全球在研乙肝新药实时进展追踪(更新至2019年11月6日)
药物名称/代号作用机制公司状态
干扰素类: 模仿体内自然产生的抗感染免疫物质
干扰素a-2b  免疫调节剂Merck,USA1991获批
派罗欣免疫调节剂Genentech, USA 2005获批
核苷(酸)类似物: 干扰用于HBV复制的病毒DNA聚合酶
拉米夫定(Lamivudine)抑制病毒DNA聚合酶GlaxoSmithKline  (GSK)1998获批
阿德福韦酯(Adefovir dipivoxil)抑制病毒DNA聚合酶Gilead Sciences, USA2002获批
恩替卡韦(Entecavir)抑制病毒DNA聚合酶Bristol-Myers Squibb, USA2005获批
替比夫定(Telbivudine)抑制病毒DNA聚合酶Novartis,USA2006获批
富马酸替诺福韦二吡呋酯(TDF)抑制病毒DNA聚合酶Gilead Sciences2008获批
替诺福韦艾拉酚胺(TAF)替诺福韦前药Gilead Sciences 2016获批
克拉夫定(Clevudine)抑制病毒DNA聚合酶Bukwang,S.Korea 2006获批
Besivo(besifovir)抑制病毒DNA聚合酶Ildong Pharma,S.Korea 2017获批

直接作用抗病毒药物: 靶向病毒并干扰HBV复制过程 
TDF 前药:一种改良的替诺福韦药物,可以更容易地进入肝细胞
TXL(CMX 157)替诺福韦前药ContraVir, USAPhase II
沉默RNA(siRNAs):干扰和破坏病毒RNA
RG6004 RNAi  锁核酸寡核苷酸(locked nucleic acid oligonucleotide )Roche,SwitzerlandPhase  I/II
ARO-HBV(JNJ-3989)RNAi Arrowhead Pharma,USAPhase  I/II
AB-729RNAi Arbutus Biopharma,USAPhase I
Vir-2218( ALN-HBV02)RNAi Alnylam and Vir Biotech,USAPhase  II
DCR-HBVSRNAi Dicerna,USAPhase I
STSG-0002RNAi Staidson,ChinaPhase I
BB-103RNAi Benitec,AustraliaPreclinical
Lunar-HBVRNAi Arcturus,USA with Janssen Preclinical
进入抑制剂:干扰HBV进入肝细胞
Myrcludex B(bulevirtide)进入抑制剂Hepatera,Russia with MYR GmbH, GermanyPhase IIb
贺普拉肽(hepalatide)进入抑制剂Hepu ,ChinaPhase II/III
衣壳抑制剂:干扰病毒DNA蛋白屏障
Morphothiadin (GLS4)衣壳抑制剂HEC Pharma,PR ChinaPhase II
JNJ 56136379衣壳抑制剂Janssen,ScotlandPhase II
JNJ-0440衣壳抑制剂Janssen,ScotlandPhase I
ABI-H0731衣壳抑制剂Assembly Biosciences,USAPhase II
EDP-514衣壳抑制剂Enanta Pharma, USAPhase I




ABI-H2158衣壳抑制剂Assembly Biosciences,USAPhase I
RG7907衣壳抑制剂Roche,SwitzerlandPhase I
QL-007衣壳抑制剂Qilu, ChinaPhase I
GLP-26衣壳抑制剂Emory UniversityPreclinical
EP-027367衣壳抑制剂Enanta Pharmaceuticals,USAPreclinical
QL-0A6a衣壳抑制剂Qilu,  China Preclinical
CB-001衣壳抑制剂ZhiMeng Biopharma,ChinaPreclinical
KL060332衣壳抑制剂KELUN,China
Phase I
HBsAg抑制剂:干扰HBV表面抗原(sAg)的产生
REP 2139sAg 抑制剂Replicor, CanadaPhase II
REP 2165sAg 抑制剂Replicor,Canada

Phase II

GST-HG131sAg 抑制剂Cosunter Co., Ltd. ChinaPhase I
反义分子:与病毒mRNA结合,防止其转变为病毒蛋白
IONIS-HBVRx (GSK3228836)病毒蛋白抑制剂Ionis Pharma,USA with GSKPhase II
IONIS-HBVLRx (GSK33389404)病毒蛋白抑制剂Ionis Pharma with GSKPhase II
HBV RNA去稳定剂(RNA destabilizer干扰RNA转录
AB-452病毒RNase抑制剂Arbutus Biopharma,USAPreclinical

间接作用抗病毒:靶向人体免疫系统攻击HBV病毒
治疗性疫苗:刺激免疫系统作为治疗的疫苗技术
 Nasvac(ABX203改进版)治疗性疫苗Center for Genetic Engineering and Biotechnology, CubaPhase II
AIC 649治疗性疫苗AiCuris,GermanyPhase I
INO-1800治疗性疫苗Inovio, USAPhase I
HB-110治疗性疫苗Ichor Medical Systems with Janssen,USAPhase I
TG1050(T101)治疗性疫苗Transgene,FrancePhase I
HepTcell治疗性疫苗Altimmune,USAPhase I
JNJ 64300535治疗性疫苗Janssen, IrelandPreclinical
HBV治疗性疫苗GeoVax Labs,USAPreclinical
VBI-2601 治疗性疫苗VBI Vaccines,USA with Brii BiosciencesPreclinical
Chimigen HBV治疗性疫苗Akshaya Bio Inc., CanadaPreclinical
CARG-201治疗性疫苗CaroGen  CropPreclinical
先天免疫防御途径:激活先天免疫系统的化合物
Inarigivir(SB9200)RIG-1和NOD2激动剂Spring Bank Pharmaceuticals,USAPhase II
GS9688TLR-8 激动剂Gilead Sciences, USAPhase II
RG7854TLR-7 激动剂Roche,Switzerland Phase  I
JNJ-4964TLR-7 激动剂Janssen,ScotlandPhase  I
TQ-A3334TLR-7 激动剂正大天晴Phase  I
宿主作用途径:诱导程序性细胞死亡(细胞凋亡)的化合物
APG-1387细胞凋亡诱导剂Ascentage Pharma,ChinaPhase I
CRV431(CPI431-32)亲环蛋白抑制剂Hepionpharma,USAPhase I
基因编辑
EBT106CRISPR/Cas  9Excision Biotherapeutics,USAPreclinical
HBV ARCUSPrecision Biopharma,USA with GileadPreclinical
其它
GC1102sAg 单克隆抗体Green Cross,South KoreaPhase II
RG6084宿主靶向锁核酸(LNA)Roche, SwitzerlandPhase  I 
EYP001FXR 激动剂Enyo Pharma,FrancePhase  I 
LTCR-H2-1T Cell 免疫疗法Lion TCR,SingaporePreclinical
IMMTavT Cell 免疫调节剂Immunocore,USAPreclinical
HBVMicroRNARegulus Therapeutics,USAPreclinical
RG6217宿主靶向锁核酸 (LNA)Roche, SwitzerlandPhase  I 
丁型肝炎病毒 (HDV)
Lambda(Pegylated Interferon)免疫调节剂Eiger Biopharma,USAPhase III
Myrcludex B(bulevirtide)进入抑制剂MYR-GmbH,GermanyPhase III
Lonafarnib异戊烯化抑制剂Eiger Biopharma, USAPhase II
REP 2139/REP 2165HBsAg 抑制剂Replicor,CanadaPhase II
EzetimibeNTCP 抑制剂Ziauddin University Hospital,PakistanPhase II
ALN-HDVRNAi Alnylam, USAPreclinical
GI-18000免疫反应刺激剂GlobeImmunePreclinical



注:来源:肝脏时间(HeparSpace) 微信公众号


声明:
不要轻信任何医疗广告或新闻报道式广告!
本站所刊载的信息仅供参考,不能代表医生的诊断和治疗,请勿直接对照治疗而延误病情!

如本文对您有用,欢迎随意打赏亿知!

捐助本站